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This document is the report of a task group of the AAPM and has been prepared primarily to advise
medical physicists involved in the external-beam radiation therapy of patients with thoracic, ab-
dominal, and pelvic tumors affected by respiratory motion. This report describes the magnitude of
respiratory motion, discusses radiotherapy specific problems caused by respiratory motion, explains
techniques that explicitly manage respiratory motion during radiotherapy and gives recommenda-
tions in the application of these techniques for patient care, including quality assurance QA
guidelines for these devices and their use with conformal and intensity modulated radiotherapy. The
technologies covered by this report are motion-encompassing methods, respiratory gated tech-
niques, breath-hold techniques, forced shallow-breathing methods, and respiration-synchronized
techniques. The main outcome of this report is a clinical process guide for managing respiratory
motion. Included in this guide is the recommendation that tumor motion should be measured when
possible for each patient for whom respiratory motion is a concern. If target motion is greater than
5 mm, a method of respiratory motion management is available, and if the patient can tolerate the
procedure, respiratory motion management technology is appropriate. Respiratory motion manage-
ment is also appropriate when the procedure will increase normal tissue sparing. Respiratory motion
management involves further resources, education and the development of and adherence to QA
procedures. © 2006 American Association of Physicists in Medicine. DOI: 10.1118/1.2349696
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implementation of respiratory motion management technology. Sadly, Dr. Kubo passed away during the formulation of this
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I. INTRODUCTION AND SCOPE
A. How to read this document
Readers are urged to review the general respiratory mo-
tion issues described in Secs. I–V D. Those interested in spe-
cific respiratory motion management techniques will find
those described in subsections of Sec. VI, which comprises
the bulk of the report. Readers interested in process-specific
issues, such as patient selection, treatment or QA issues, will
find those described in further subsections under each of the
technique-specific subsections. The summary and recom-
mendations are given in Sec. VII.
B. Introduction
Intrafraction motion is an issue that is becoming increas-
ingly important in the era of image-guided radiotherapy. In-
trafraction motion can be caused by the respiratory, skeletal
muscular, cardiac, and gastrointestinal systems. Of these four
systems, much research and development to date has been
directed towards accounting for respiratory motion. The
management of respiratory motion in radiation oncology is
the subject of this task group report.
Respiratory motion affects all tumor sites in the thorax
and abdomen though the disease of most prevalence and rel-
evance for radiotherapy is lung cancer. Lung cancer accounts
for 28% of all cancer deaths in the U.S. American Cancer
Society Cancer Facts and Figures 2004. An estimated
173,770 new cases were diagnosed in 2004, with an esti-
mated 160,440 deaths. American Cancer Society Cancer
Facts and Figures 2004. The five-year survival rate for all
3876 Keall et al.: Respiratory motion in radiation oncology 3876stages combined is 15%. American Cancer Society Cancer
Facts and Figures 2004. However, there is clinical evidence
of a local control and survival advantage for higher dose
levels.1–9 Lung complications have been shown to correlate
with mean lung dose or similar surrogate, such as V20.10–15
The need for normal tissue sparing is of increasing impor-
tance due to the growing use of concomitant chemotherapy.
Thus, there is clinical evidence that technologies that allow
an increased dose to the tumor while sparing healthy tissue
will improve the balance between complications and cure.
It is important to note that respiratory motion is just one
potential source of error in radiotherapy. Other important er-
rors such as large inter-physician GTV variations for lung
cancer
16–19
and CTV variations for breast cancer20,21 have
been published. The dosimetric consequences of these varia-
tions are almost an order of magnitude larger than those
caused by respiration-induced motion see Sec. IV. Also,
setup errors for lung18,22–28 and breast29–36 cancer are of the
same or of a higher order than those of respiratory motion.
Respiratory motion varies from day to day, and tumor and
normal tissues can shrink, grow, and shift in response to
radiation therapy and potentially to other concomitant
therapies.
C. Scope
Methods that are used in the management of respiratory
motion in radiation oncology and that are covered by this
report include:
• Motion-encompassing methods;
• respiratory gated techniques;
• breath-hold techniques;
• forced shallow-breathing methods;
• respiration-synchronized techniques.
It is recognized that most facilities currently do not have
access to methods that explicitly account for respiratory mo-
tion, and, thus, guidelines for treatments at these facilities are
also included in the “Motion-encompassing methods” sec-
tion. Note that respiratory management methods are not re-
quired for all patients.
The emphasis of this task group is on techniques that have
been clinically implemented and used to treat patients. Less
emphasis is placed on techniques that have been published
and are under development, but have yet to be implemented
in patient treatments. While there has been work on jet ven-
tilation techniques37–40 and other emerging technology, these
methods will not be discussed further here.
Some of the imaging methods involved in the manage-
ment of respiratory motion involve the application of addi-
tional ionizing radiation. The benefit of the additional imag-
ing information should be weighed against the potential risks
associated with the extra patient dose. Readers are referred to
the report currently being compiled of AAPM Task Group
75 “Radiographic imaging doses in radiation therapy.”
Medical Physics, Vol. 33, No. 10, October 2006Charged-particle therapy delivery is not explicitly ad-
dressed, although many of the procedures are applicable to
charged particle therapy, given the additional concern of the
variation in particle range caused by respiratory motion.
II. GLOSSARY AND ABBREVIATIONS
This section will contain abbreviations of commonly used
terms from the report as well as suggested terminology for
instances when multiple words or phrases are used to de-
scribe the same object or function, such as:
4D Four-dimensional
ABC Active-breathing control
CTV Clinical target volume41,42
Deep exhalation Maximum expiratory level43
Deep inhalation Maximum inspiratory level43
DIBH Deep-inspiration breath hold
DRR Digitally reconstructed
radiograph
Duty cycle The fraction of time a radiation
beam is active during the delivery of a
respiratory gated treatment field
Exhalation Resting expiratory level43
FB Free breathing
Gate A device that for this application
restricts image acquisition or treatment
delivery to a particular part of the
respiratory cycle
GTV Gross tumor volume41,42
Hysteresis The lagging of an effect e.g., tumor
motion behind its cause e.g., muscular
contractions resulting in the tumor
taking a different path during inhalation
and exhalation
Inhalation Resting inspiratory level43
Interfraction Occurring between treatment sessions
Intrafraction Occurring within a treatment session
Phase A particular stage in a periodic process
e.g., regular respiratory motion.
Physicist A qualified medical physicist as defined
by the AAPM www.aapm.org/
medical_physicist/fields.asp
PTV Planning target volume41,42
Range of motion Displacement between inhalation and
exhalation
RC Respiratory correlated
Respiratory gated The synchronization of imaging and
radiation delivery with respiration, such
that image acquisition/radiation delivery
only occurs during a certain part of the
respiratory cycle
Respiratory
synchronized
The synchronization of radiation delivery
with respiration via movement of the
linear accelerator or the patient such
that the radiation beam is following the
tumor during treatment
Spirometer A device that measures the volume of air
entering and exiting the lungs
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DURING RADIOTHERAPY
A. Image-acquisition limitations
If respiratory motion is not accounted for, as is the case
when conventional radiotherapy techniques are applied in
thoracic and abdominal sites, it causes artifacts during image
acquisition. Motion artifacts are commonly seen with tho-
racic CT images. An example of the difference between a
respiratory gated and a nongated CT scan for a patient is
shown in Fig. 1. Artifacts from CT scans manifest them-
selves as target/normal tissue delineation errors and ad-
versely affect dose-calculation accuracy. It is important to
note that respiratory motion can generate artifacts for all im-
aging modalities, including positron emission tomography
PET scanning.44–47
B. Treatment-planning limitations
During treatment planning, margins need to be large
FIG. 1. Coronal views of CT scans of the same patient taken a during free
breathing FB and b with respiratory gated scanning at exhalation. From
Ref. 140.enough to ensure coverage of the target for most of the treat-
Medical Physics, Vol. 33, No. 10, October 2006ment delivery. Generally, for CT-planned lung cancer treat-
ments, the gross tumor volume GTV41,42 is outlined, and a
margin is added to include the suspected microscopic
spread48 which when added to the GTV creates the clinical
target volume CTV. Thus, using ICRU 6242 nomenclature,
to obtain the planning target volume PTV from the CTV
involves margins to account for intrafraction motion, inter-
fraction motion, and setup error. Accounting for respiratory
motion by adding treatment margins to cover the limits of
motion of the tumor is suboptimal, because this increases the
radiation field size and consequently the volume of healthy
tissues exposed to high doses. However, if the margins are
not sufficiently large, part of the CTV will not receive ad-
equate dose coverage. Because of the artifacts observed in
CT images in which respiratory motion has not been ac-
counted for, the magnitude of margin to allow for respiratory
motion is difficult to quantify, particularly for individual pa-
tients in whom a wide range of tumor motion is
observed.49,50
C. Radiation-delivery limitations
Radiation delivery in the presence of intrafraction organ
motion causes an averaging or blurring of the static dose
distribution over the path of the motion while inter-fraction
motion causes a shift of the dose distribution. This displace-
ment results in a deviation between the intended and deliv-
ered dose distributions. Assuming a static beam, the total
positional error affecting the dose is the composite vector of
internal e.g., tumor-bone and external bone-treatment
room displacements. Thus, for conventional non-intensity
modulated radiation therapy IMRT treatments, in which
the dose gradient in the center of each field can be assumed
to be fairly small, the effect is manifested by a blurring of the
dose distribution by the anatomy moving near the beam
edges, in effect increasing the beam penumbra. This effect is
thought to be exacerbated during IMRT delivery, causing
motion artifacts in dose distribution due to the interplay be-
tween motion of the leaves of a multileaf collimator MLC
and the component of target motion perpendicular to the
beam. Further discussion of IMRT effects is given in Sec.
V C.
IV. MAGNITUDE AND MEASUREMENT OF
RESPIRATORY MOTION
A. The mechanics of breathing
The primary function of the lung is to facilitate gas O2
and CO2 exchange between blood and air, thus maintaining
normal levels of gas pressure partial pressure of oxygen,
PO2, and partial pressure of carbon dioxide, PCO2 in the
arterial blood. Respiration is an “involuntary” action; i.e., a
person would continue to breathe despite being unconscious.
However, within limits, individuals are capable of control-
ling the frequency and displacement magnitude of their res-
piration as well as breath holds. Unlike cardiac motion, the
3878 Keall et al.: Respiratory motion in radiation oncology 3878respiratory motion is not rhythmic. The periodic cycle of
respiration is regulated through chemoreceptors by the levels
of CO2, O2, and pH in the arterial blood.
Anatomically, the lungs are held within the thoracic cav-
ity, encased by the liquid-filled intrapleural space. Inhalation
requires active participation of respiration muscles. During
the inhalation part of quiet breathing, the increasing volume
of the thoracic cavity draws air into the cavity. The most
important muscle of inhalation is the diaphragm. As the dia-
phragm is contracted, it descends and the abdomen is forced
inferiorly and anteriorly, increasing the superior-inferior SI
dimension of the chest cavity. The intercostal muscles con-
nect adjacent ribs and also participate in normal inhalation.
They contract during inhalation, pulling the ribs superiorly
and anteriorly, thereby increasing both the lateral and
anterior–posterior AP diameters of the thorax. Exhalation
is passive for quiet breathing. The lung and chest walls are
elastic and return passively to their pre-inhalation positions
at exhalation. Other ventilation muscles are involved only
during active exhalation.
Transpulmonary pressure, the pressure difference between
respired gas at the mouth and the pleural pressure around the
lungs, is reduced during inhalation and is recovered during
exhalation. During normal breathing, the deflating lung vol-
ume is larger than the inflating volume at the same transpul-
monary pressure. This is called “hysteresis,” attributable to
the complex respiratory pressure volume relationship of the
lung and chest wall.
Breathing pattern characterization measurements have
been distinguished by posture upright, prone, supine, lateral
decubitus, breathing type chest or abdominal, and depth of
respiration shallow, normal, deep. During normal respira-
tion, the lung volume typically changes by 20% from 3.3
to 4.1 on average in a 10-patient study51; at deep inhala-
tion, the increase in lung volume is approximately three to
four times that of normal breathing.52
B. Measuring respiratory motion
The lungs, esophagus, liver, pancreas, breast, prostate,
and kidneys, among other organs, are known to move with
breathing. We provide here a survey of published observa-
tions on organ motion due to respiration and other influences.
The survey is not exhaustive, but is intended to provide
guidelines for accommodating the motion during treatment.
In many cases, the object being measured is the tumor or
host organ itself, while in other cases it is an artificial marker
implanted in or near the tumor, a surrogate organ such as the
diaphragm.
Patients’ breathing patterns can vary in magnitude, period
and regularity during imaging and treatment sessions,50,53–55
as demonstrated in Fig. 2. Systematic changes in the respi-
ratory baseline also occur. Motion also varies markedly be-
tween patients, indicating that an individual approach to res-
piratory management is advised. Audio-visual
biofeedback54–56 has been demonstrated to improve respira-
tory reproducibility.
Medical Physics, Vol. 33, No. 10, October 2006C. Motion observables and observations
Organ motion has been detected via ultra-
sound,57–59 CT,60–63 magnetic resonance MR,64,65 nuclear
medicine,66,67 and fluoroscopy.22,24,32,50,68–80 Respiratory mo-
tion studies have tracked the movement of the
tumor,24,49,60,61,74,79,80 the host organ,57–59 radiographic fidu-
cial markers embedded at the tumor site,32,50,69,72,73,78 and
surrogate organs, such as the diaphragm, which are assumed
to correlate with the tumor.53,63,71,76 These data are summa-
rized in Tables I lung and II abdomen.
Four-dimensional or respiratory correlated CT81–88 using
single-slice, multislice or cone-beam acquisition can provide
three-dimensional 3D data on tumor position at several
points along the breathing cycle with a somewhat reduced
temporal resolution, as compared with conventional CT, thus
providing a compromise between the good time resolution of
a fluoroscopic study and the detailed 3D information of a CT
scan.
The investigators referenced in this section have pub-
lished data based on anywhere from four75,77 to fifty-one67
subjects. Most of the published reports are based on cohorts
of ten to thirty subjects. For the tumor sites discussed in this
report, each set of published data has been condensed into a
mean displacement and a full range of observed displace-
ments.
Generally, abdominal organ motion is in the SI direction,
with no more than a 2 mm displacement in the AP and lateral
directions.58,64 However, in some individuals, the kidneys
show more complex patterns.58 Lung tumor motions gener-
ally show a much greater variation in the trajectory of mo-
tion.
The amount a lung tumor moves during breathing varies
widely. Stevens et al.49 found that out of 22 lung tumor pa-
FIG. 2. Variations in respiratory patterns from the same patient taken a few
minutes apart. The three curves in each plot correspond to infra-red reflector
measured patient surface motion in the SI, AP, and ML directions, with each
component arbitrarily normalized. In a, the motion pattern is relatively
reproducible in shape, displacement magnitude, and pattern. In b, the trace
is so irregular that it is difficult to distinguish any respiratory pattern. Figure
courtesy of Dr. Sonja Dieterich.tients, ten subjects showed no tumor motion in the SI direc-
3879 Keall et al.: Respiratory motion in radiation oncology 3879tion. Of the remaining 12 subjects, the average SI displace-
ment was anywhere from 3 to 22 mm mean 8±4 mm. They
found no correlation between the occurrence or magnitude of
tumor motion and tumor size, location, or pulmonary func-
tion, suggesting that tumor motion should be assessed indi-
vidually. Seppenwoolde et al.50 measured 3D trajectories for
20 patients via dual real-time fluoroscopic imaging of a fi-
ducial marker implanted in or near the tumor. They observed
TABLE I. Lung tumor-motion data. The mean range
meters for each cohort of subjects. The motion is in t
left-right; SI: superior-inferior.
Observer S
Barnes: Ref. 74 Lower lobe 18.5 
Middle, upper lobe 7.5 2
Chen Ref. 73 0–5
Ekberg Ref. 22 3.9 0
Engelsman: Ref. 24
Middle/upper lobe 2–
Lower lobe 2–
Erridge Ref. 104 12.5 
Ross: Ref. 60 Upper lobe -
Middle lobe -
Lower lobe -
Grills Ref. 80 2–3
Hanley Ref. 61 12 1
Murphy Ref. 77 7 2–
Plathow: Ref. 65 Lower lobe 9.5 4.5
Middle lobe 7.2 4.3
Upper lobe 4.3 2.
Seppenwoolde Ref. 50 5.8 0
Shimizu Ref. 75 -
Sixel Ref. 79 0–1
Stevens Ref. 49 4.5 0
TABLE II. Abdominal motion data. The mean range of motion and the
minimum-maximum ranges in millimeters for each site and each cohort of
subjects. The motion is in the superior-inferior SI direction.
Site Observer
Breathing mode
Shallow Deep
Pancreas Suramo Ref. 57 20 10–30 43 20–80
Bryan Ref. 59 20 0–35 -
Liver Weiss Ref. 66 13±5 -
Harauz Ref. 67 14 -
Suramo Ref. 57 25 10–40 55 30–80
Davies Ref. 58 10 5–17 37 21–57
Kidney Suramo Ref. 57 19 10–40 40 20–70
Davies Ref. 58 11 5–16 -
Diaphragm Wade Ref. 68 17 101
Korin Ref. 64 13 39
Davies Ref. 58 12 7–28 43 25–57
Weiss Ref. 66 13±5 -
Giraud Ref. 63 - 35 3–95
Ford Ref. 76 20 13–31 -Medical Physics, Vol. 33, No. 10, October 2006hysteresis in the trajectories of half the patients, amounting
to a 1 to 5 mm separation of the trajectories during inhala-
tion and exhalation, with four out of 20 patients exceeding a
2 mm separation. This indicates that in cases where high
accuracy is required in dose alignment, a real-time tracking
or gating process based on surrogate breathing signals should
not only correlate with the tumor’s motion along each axis
with the breathing signal, but should have knowledge of the
respiratory phase, because the phase difference is what leads
to the hysteresis effect. In Fig. 3, motion trajectories during
radiotherapy of lung tumors, measured using implanted gold
markers, are depicted.50
D. Summary of motion observations
A review of the respiratory motion literature leads to the
following conclusion: There are no general patterns of respi-
ratory behavior that can be assumed for a particular patient
prior to observation and treatment. The many individual
characteristics of breathing—quiet versus deep, chest versus
abdominal, healthy versus compromised, etc.—and the many
motion variations associated with tumor location and pathol-
ogy lead to distinct individual patterns in displacement, di-
rection, and phase of tumor motion.
In many cases, it is difficult or impossible to observe the
tumor directly during treatment delivery prompting research-
ers to observe surrogate structure motion expected to have a
close relationship with the tumor motion. If a surrogate
structure, such as the chest wall or diaphragm, is used to
tion and the minimum-maximum ranges in milli-
dimensions SI, AP, LR. AP: anterior-posterior; LR:
Direction
AP LR
- -
- -
- -
2.4 0–5 2.4 0–5
- -
- -
9.4 5–22 7.3 3–12
1 0–5 1 0–3
0 9 0–16
1 0–4 10.5 0–13
0–10 0–6
5 0–13 1 0–1
- -
 6.1 2.5–9.8 6.0 2.9–9.8
 4.3 1.9–7.5 4.3 1.5–7.1
 2.8 1.2–5.1 3.4 1.3–5.3
2.5 0–8 1.5 0–3
6.4 2–24 -
0–5 0–4
- -of mo
hree
I
9–32
–11
0
–12
6
9
6–34
0
–20
15
–16.4
–10.2
6–7.1
–25
3
–22signal tumor position for the purpose of beam gating or
3880 Keall et al.: Respiratory motion in radiation oncology 3880tracking, without observing the tumor directly during treat-
ment, there will be uncertainties in the displacement and
phase relationship between the surrogate and the tumor89–91
or other anatomy.53,92,93 A summary of such studies is given
in Table III. It needs to be stressed that both surface markers
and spirometers provide signals that are surrogates of tumor
motion. Their applications should be validated by the users
performing fluoroscopic and CT imaging studies. In a gating
approach to motion compensation, the displacement correla-
tion does not need to be known explicitly, because one is not
trying to predict the absolute tumor position from the surro-
gate motion signal. The surrogate breathing signal only
needs to indicate the phase of the breathing motion. How-
ever, it cannot be assumed a priori that the phase of the
TABLE III. Correlation of tumor/organ motion with the respiratory signal. 3D
Magnetic resonance imaging; s: Seconds; SI: Superior-inferior.
Organ/source
Respiratory
signal
N patients
measurements
Diaphragm SI
fluoroscopy
Abdominal
displacement
5 60
Tumor and
diaphragm,
fluoroscopy
Abdominal
displacement
43
Tumor, SI
fluoroscopy
Spirometry and
abdominal
displacement
11 23
Tumor, 3D
biplane
radiography
Abdominal
displacement
26
Lung vessels,
cine MRI
Abdominal
displacement
4
Lung tumor,
respiration-correlated
CT
Abdominal
displacement
9 where tumor SI
motion 5 mm
Lung tumor, SI
respiration-correlated
CT
Diaphragm
position
12Medical Physics, Vol. 33, No. 10, October 2006organ motion matches the phase of the surrogate motion, nor
can it be assumed that the phase relationship is stationary. In
fact, nonzero phase differences are evidence of either insta-
bility and nonstationary time behavior or multiple driving
forces in complex oscillatory mechanical systems. These will
be especially significant in the lung, where the mechanical
coupling between the tumor and the surrogate structure is
often weak, resulting in complex relationships between the
two, and the breathing forces from the chest and/or the dia-
phragm. It should also be mentioned that implanted fiducial
markers are also a surrogate for tumor motion, and their
accuracy in depicting true tumor motion has yet to be
studied.
FIG. 3. Tumor trajectories not to scale in 23 lung tu-
mor patients, measured using implanted markers and
real-time stereoscopic fluoroscopy. From Ref. 50.
ree-dimensional; AP: Anterior-posterior; CT: Computed tomography; MRI:
Correlation
range Phase shift Source
0.82–0.95 Not observed Vedam et al. Ref. 53
0.41–0.94 Short delays
observed
Ahn et al. Ref. 89
0.39–0.99 −0.65–0.5 s Hoisak et al. Ref. 90
Respiratory
waveform cycle
agreed with SI
and AP tumor
motion
Principally
within 0–0.3 s
existence of 
1.0 s
Tsunashima
et al. Ref. 91
SI 0.87±0.23, - Koch et al. Ref. 92
AP 0.44±0.27
0.74–0.98 1 s 4 pts Mageras et al. Ref. 87
0.5 s 5 pts
0.73–0.96 1 s 4 pts Mageras et al. Ref. 87
0.5 s 5 pts: Th
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MANAGEMENT
Issues that are common to all methods of respiratory mo-
tion management are discussed in this section, including
treatment planning, QA, IMRT, and workload.
A. Treatment planning
Two useful articles that discuss important principles and
provide guidelines for treatment planning for lung cancer
radiotherapy have been published by Senan et al.94,95 The
main geometric consideration for treatment planning once
the GTV and CTV have been defined is the CTV-PTV mar-
gin, which accounts for estimated geometric errors. In terms
of target motion, the effect of all geometrical uncertainties is
a displacement of the target during treatment relative to the
dose distribution determined from the treatment plan. Con-
sidering the target as a static structure and the dose distribu-
tion as mobile allows the dose delivered to be summed over
the time period of all fractions. When there are many frac-
tions, the random errors can be accurately described as a
blurring of the dose distribution.96 The blurring is approxi-
mated as a convolution of the dose distribution with the
probability distribution function of the total displacement
vector of the target versus the treatment machine.97,98 A con-
volution is not completely correct to describe the dose
changes see, for example, Refs. 99–101, but is quite accu-
rate in practice.102 Systematic errors cannot be accounted for
by this approach, which makes pretreatment imaging proce-
dures as described above and frequent monitoring during
treatment particularly important to reduce them. The follow-
ing components contribute to the overall geometric error and
should be considered when designing CTV-PTV margins:
• Inter- and intraobserver variations in GTV16–19 and
CTV20,21 delineation;
• motion artifacts in the CT scan, which cause target de-
lineation errors;
• respiratory motion and heartbeat during delivery,50
which are periodic functions of time;
• daily variations of respiratory motion;50,54,55,103
• variations caused by changing organ volumes;
• tumor growth and shrinkage;
• treatment-related anatomic changes, such as reductions
in bronchiole obstructions and changes in atelectasis
collapsed lung regions;
• patient setup error: Typical 3–5 mm 1 standard
deviation.18,22–28,104
Note that respiration-motion management techniques not
only affect the accuracy of target localization, but can also
play a role in normal tissue sparing.61,105 It is also important
to note that fast tumor shrinkage occurs quite often in lung
radiotherapy, which may give rise to systematic delivery
errors.
104 The combined effect of random and systematic er-
rors, including respiration, can be quantified in a dose-
probability computation106,107 or through biological
108,109
modeling.
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Quality assurance has a crucial role in all aspects of ra-
diation oncology, as outlined in the report of AAPM Task
Group 40.110 This section describes QA techniques used in
the management of respiratory motion. This section is di-
vided into general descriptions and recommendations com-
mon to different methods of accounting for respiratory mo-
tion. QA procedures specific to each technique are described
separately later.
A key issue in gated or breath-hold treatments using ex-
ternal respiratory monitors is the accuracy of such monitors
in predicting internal target-organ position. As described ear-
lier, internal/external correlation can be disturbed or lost
completely by transient changes in breathing. For these rea-
sons, patient training is important in allowing the patient to
familiarize him- or herself with the breathing technique and
for evaluating his or her ability to achieve reproducible res-
piratory signals. Breath-hold methods in particular require
active patient participation. They also call for special staff
effort, as therapists must be trained to coach and advise the
patients. The limitations of equipment should also be under-
stood for example spirometer drifts so that when issues
occur during simulation or treatment the diagnosis and cor-
rection of the issue is timely.
Some respiratory motion management techniques involve
additional devices that come into contact with the patient,
thus hygiene practices for the safety of the patient and the
staff need to be established. Generally, devices that come
into contact with patient mucosal surfaces should be dis-
carded after use; devices that come into contact with the
patient skin can be reused provided appropriate procedures
are followed.
Frequency: As with all QA procedures, the appropriate
tests should be performed after any hardware or software
changes or after service or changes to the respiratory motion
management device itself or the equipment CT scanner,
fluoroscope or linear accelerator interfacing with the respi-
ratory motion management device. Furthermore, until famil-
iarity with the system is sound, QA may be performed more
frequently as determined by the physicist and the nature of
the test.
Patient training: The ability to achieve reproducible
breathing or breath-hold patterns is a requirement for allow-
ing the patient to proceed to simulation and treatment. In
particular, this affects the self-consistency of a CT scan that
spans multiple respiratory cycles or breath holds and the re-
producibility of patient anatomy between simulation and
treatment. Prior to the start of simulation, the patient should
be made familiar with the equipment and its purpose. A
physicist or trained designee should perform the coaching
and evaluation at least in the initial clinical implementation.
For breath-hold techniques, the training session, consisting
of a series of breath holds in the treatment position, estab-
lishes the patient’s respiratory level for treatment and breath-
hold duration.
Simulation: By viewing the patient with fluoroscopy or
ciné CT, the magnitude of respiratory motion and the corre-
3882 Keall et al.: Respiratory motion in radiation oncology 3882lation between the tumor motion and the respiratory signal
can be evaluated. For breath-hold techniques, one should
verify that the tumor position or other anatomic surrogates if
the tumor is not visible is stable within each breath hold and
reproducible between breath holds. Patients who cannot hold
their breath for the entire duration of the CT scan will require
segmentation of the scan region ideally not through the tar-
get to permit shorter breath holds. If the potential exists that
the patient will be unable to comply with breathing or
breath-hold techniques for treatment, a backup CT scan with-
out such a requirement is recommended during simulation.
Treatment: At the start of the first treatment fraction, the
patient should be reacquainted with the equipment, including
practiced controlled breathing or breath holds. For breath-
hold techniques, it is preferable to deliver a treatment field in
a single breath hold. If the duration of this breath hold is too
long for patient comfort, careful documentation in the chart
should be made about break points for individual beams. The
therapists will need to monitor the treatment machine, the
patient, and the gating or breath-hold system display.
Radiographs to check internal constancy: Although exter-
nal monitors may correlate well with the respiratory organs
within a single session, thus reducing intrafractional varia-
tions, the relationship between external monitor and internal
organ positions may change between sessions, which can
adversely affect organ reproducibility and produce interfrac-
tional variations. A program of frequent radiographs of the
surrogate organ or target, if visible throughout treatment is
essential to measure interfractional variations and should be
acquired during the respiratory cycle part or breath hold used
for simulation and treatment. Sometimes, lung tumors are
sufficiently discernible in the radiographs to allow direct
confirmation of their position. Daily verification is recom-
mended for the first few treatments, followed by at least
weekly verification to ensure that the anatomy at the respi-
ratory position used for treatment remains constant. If the
radiographs indicate differences from simulation, the dosim-
etric consequences and remedies are evaluated by the physi-
cist and the physician. For treatment machines with an exit
detector, more advanced verification techniques are possible.
For example, ciné-mode acquisition, by which several im-
ages are acquired during each field delivery, may be utilized.
As with all radiotherapy procedures, constant vigilance by
the treatment staff is important. Training and education for
all staff involved with respiratory management, as well as
periodic retraining, is recommended. A physicist should be
available to solve any hardware-related problems.
C. Intensity modulated radiation therapy
IMRT has seen widespread application owing to its ability
to conform the spatial distribution of the dose deposited in a
patient more effectively. The implications for targets in the
thoracic and abdominal regions have been particularly im-
portant due to the many organs at risk in these regions. How-
ever, respiratory motion intuitively presents considerable is-
sues for IMRT delivery, since beam-intensity gradients are
no longer confined solely to the edges of the beams. Rather,
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collimators. Thus, if a target is also moving inside this same
field with its own period unique from the MLC leaves and
possibly deforming, it is easy to understand why there are
concerns over the use of IMRT with targets affected by res-
piratory motion. Yu et al.111 see also Kissick et al.112 dem-
onstrated this effect using theoretical models that yielded
dose variations for “clinically relevant parameters” of up to
100%. In a dynamic wedge simulation, Pemler et al.113
showed that the magnitude of dosimetric errors may ap-
proach 15% for a single dynamic wedge treatment. Bortfeld
et al.114 demonstrated dosimetric errors on the order of ±8%
for a single point in the middle of the treatment field low-
dose gradient region in the simulation of a single IMRT
treatment. Kubo and Wang115 and Keall et al.116 analyzed the
dosimetric error for a single MLC-based IMRT treatment
using film. In each study, films of treatments delivered with
and without motion were compared. To simulate motion, film
was moved a distance and at a rate consistent with respira-
tory motion. Errors of up to 20% were reported within the
field low-dose gradient region, with even larger errors on
the edges of the field high-dose gradient regions.
Based on these findings, it would seem that the concern
over potential dosimetric error introduced by respiratory mo-
tion for IMRT treatments is justified; however, Yu et al.111
showed that fluence variations within a moving target tend to
average out over the typical course of 30 fractions, when one
assumes that the breathing phase or frequency is random
from day to day. Along similar lines, Bortfeld et al.114
showed that dosimetric errors introduced by respiratory mo-
tion also tend to average out with fractionation; this was
further supported in MLC-based IMRT studies by George et
al.117 and Chui et al.118
In a follow-up study, Jiang et al.119 experimentally veri-
fied the findings of Bortfeld et al.114 for a single point in a
low-dose gradient region using MLC-based IMRT; however,
these studies assumed or applied simplistic, one-dimensional
1D motion, which can be quite different from the real,
complex phenomenon of breathing.50,78 Furthermore, target
deformation may be present, although this deformation has
yet to be quantified. They, therefore, cautioned that fraction-
ation alone should not be relied on, at least in cases of large
1 cm motion, until their findings could be verified under
more realistic conditions.
To summarize, the above studies indicate that caution is
warranted when considering IMRT for targets subject to res-
piratory motion, particularly for single or few-fraction treat-
ments common for stereotactic body radiotherapy. For indi-
viduals who still intend on using IMRT without any direct
motion-correction strategy, it needs to be emphasized that the
full extent of breathing motion should be assessed and con-
sidered when assessing margins for the treatment plan. Even
with correction strategies, there can still be residual target
motion with respect to the beam, for example, with respira-
tory gated treatment, which may exhibit similar, albeit
smaller, effects.
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Respiratory motion management techniques utilize spe-
cific technology that requires increased medical supervision
and longer treatment times for the delivery of this precise
treatment. Additional physics, physician and therapist sup-
port is required during the simulation, planning and treat-
ment processes, which are described in more detail below. If
imaging procedures are performed, further resources are in-
volved. When acquiring a respiratory management device for
clinical use, there are capital costs, staff training costs and
time, acceptance testing and commissioning procedures to be
performed as well as the development and execution of on-
going QA and staff education and training programs.
Before simulation, the scheduling of patients that are
identified by physicians includes relaying the information
about potential patients to the physics group. Depending on
the respiratory management technique, the physics group
may need to schedule a training session with the patient,
which can take up to one hour with the patient and an addi-
tional half-hour to full hour to assemble the equipment for
this training session. A physicist or designated staff member
who is appropriately trained to manage the procedure then
needs to be present for the CT imaging session. The physicist
may need to evaluate the quality of the imaging study and, if
necessary, repeat the imaging study. Some respiratory man-
agement devices have patient-specific disposable accessories
that need to be ordered, purchased and stored. The treatment
planning may require special instructions and physics over-
sight which can take several hours in some cases.
At many institutions, a physicist is required to be present
for the first treatment with respiratory management proce-
dures. Coaching the patient at simulation and on the first day
of treatment is fairly common and recommended. For some
techniques and patients, further coaching is needed. Finally,
TABLE IV. Summary of intra- and inter-fractional variations for different met
breathing control, SD—standard deviation, LR—left-right, AP—anterior-p
setup error, 3D—3-dimensional error, mDIBH moderately deep inspiration
Reference Technique O
Cheung Ref. 201 BH at inspiration
with ABC
Lun
Dawson Ref. 202 BH at exhalation
with ABC
Dia
Ford Ref. 76 Gating at exhalation
with RPM
Dia
Hanley Ref. 61 DIBH Dia
Mah Ref. 160 DIBH Dia
Negoro Ref. 170 Abdominal
compression with
stereotactic body
frame
Lun
Remouchamps Ref. 203 mDIBH with ABC Dia
Wagman Ref. 133 Gating at exhalation
with RPM
Abdoma review and QA of the respiratory traces or images acquired
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requires approximately two hours of work per patient. There
are also material and machine time considerations. Time re-
quired at the CT scanner is longer, treatment times are
longer, and a room may be required for an hour-long training
session. The extra time at an accelerator has the cost of de-
creased patient throughput. There is also the capital invest-
ment, use and depreciation costs of the equipment used for
these treatments.
VI. METHODS TO ACCOUNT FOR RESPIRATORY
MOTION IN RADIOTHERAPY
Methods to reduce the impact of respiratory motion in
radiotherapy can be broadly separated into five major catego-
ries: Motion-encompassing methods, respiratory gating tech-
niques, breath-hold techniques, forced shallow-breathing
techniques, and respiration-synchronized techniques. These
methods are discussed in detail in this section. A summary of
published intra- and inter-fractional variations for the differ-
ent methods is given in Table IV.
A. Motion-encompassing methods
1. Introduction
This section discusses imaging and treatment-planning
guidelines for tumor sites affected by respiratory motion.
Since respiratory induced tumor motion will be present dur-
ing radiation delivery, it is important to estimate the mean
position and range of motion during CT imaging.
The three techniques possible for CT imaging that can
include the entire range of tumor motion for respiration at
the time of CT acquisition are slow CT, inhalation and ex-
halation breath-hold CT, and four-dimensional 4D or
respiration-correlated CT. These are listed in order of in-
of respiratory management. Abbreviations: BH—breath-hold, ABC—active
or, SI—superior-inferior, DIBH—deep inspiration breath-hold, * includes
-hold. Ref. 200.
Intra-fraction
variation cm
Inter-fraction
variation cm
or - SD: 0.18 LR, 0.23 AP, 0.35 SI
m SD: 0.25 SD: 0.44
m Mean: 0.26 Mean: 0.0
SD: 0.17 SD: 0.39
m SD: 0.25 -
m - 0.4*
or Mean 3D: 0.7 Mean 3D: 0 .5*
Range: 0.2–1.1 Range: 0.4–0.8*
m Mean: 0.14 Mean: 0.19
SD: 0.17 SD: 0.22
organs Mean: 0.20 -hods
osteri
breath
rgan
g tum
phrag
phrag
phrag
phrag
g tum
phrag
inalcreasing workload. It is important to understand that the
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tween simulation sessions and treatment sessions. Further-
more, the radiation dose to the patient from these imaging
procedures can be greater than standard CT simulation pro-
cedures by a factor of 2–15 if no efforts are made to reduce
CT dose.
2. Slow CT scanning
One solution for obtaining representative CT scans for
peripheral lung tumors is slow scanning.120–122 The CT scan-
ner is operated very slowly, and/or multiple CT scans are
averaged such that, on average, multiple respiration phases
are recorded per slice. Hence, the image of the tumor at
least in the high-contrast areas should show the full extent
of respiratory motion, provided that the scanner operates at a
particular couch position for longer than the respiratory
cycle. This technique yields a tumor-encompassing volume,
with the limitation that the respiratory motion will change
between imaging and treatment, and, thus, additional mar-
gins are required to account for these variations. In addition
to anatomic delineation, slow scanning is more advantageous
than standard scanning, because the dose calculation is per-
formed on a geometry that is more representative of that
during the entire respiratory cycle, as occurs during treat-
ment. The disadvantage is the loss of resolution due to mo-
tion blurring, which potentially leads to larger observer er-
rors in tumor and normal organ delineation. Due to motion
blurring, this method is only recommended for lung tumors
that are not involved with either the mediastinum or the chest
wall. This method is also not recommended for other tumor
sites e.g., the liver, pancreas, kidney, etc. It has been sug-
gested that PET, with its inherently long acquisition times, is
also a good solution for estimating the motion path of a
tumor;44–47 however, motion can also blur the object in the
PET image such that a suspicious lesion may not even be
apparent, in which case respiration-gated PET or 4D PET
may be a better option.
3. Inhalation and exhalation breath-hold CT
A solution to obtaining a tumor-encompassing volume
that can be implemented in most clinics is to acquire both
inhalation and exhalation gated or breath-hold CT scans of
the patient during the CT simulation session. Taking both
inhalation and exhalation CT scans will more than double the
CT scanning time and relies on the patient’s ability to hold
his or her breath reproducibly. The two scans require image
fusion and extra contouring. For lung tumors, the maximum
intensity projection123 MIP tool the MIP image in this con-
text for a set of CT images is the maximum CT number
found in a given voxel in the set available in most visual-
ization systems can be used to obtain the tumor-motion-
encompassing volume, provided there is no mediastinal tu-
mor involvement. The advantage of this approach over the
slow scanning method mentioned above is that the blurring
caused by the motion present during FB is significantly re-
duced. Dose calculation should be performed on the CT data
set that is most appropriate for the particular patient, e.g.,
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exhalation than inhalation. The exhalation scan will tend to
underestimate the lung volumes and, hence, overestimate the
percentage of lung volume receiving a specific dose. To save
time, a free-breathing CT could be used for the entire scan
region typically including the entire thoracic cavity, with
either breath-hold or gated CT scans at inhalation and exha-
lation of a scan length sufficient to cover the tumor volume
to determine the range of motion of the GTV. Some form of
respiratory monitoring is necessary to verify gating or
breath-hold constancy and to ensure that the scans are repre-
sentative of the patient’s normal breathing range.
Breath-hold scans can also potentially be used for respi-
ratory gated delivery, however, it should be noted that a res-
piratory gated CT scan is preferred over a breath-hold scan at
the same respiratory position, because the predominant res-
piratory muscles can be different for breath hold and FB
e.g., intercostal vs. diaphragm, and any tumor lag relative
to the external monitor occurring during FB will be absent
during breath hold.
4. Four-dimensional CT/respiration-correlated CT
A promising solution for obtaining high quality CT data
in the presence of respiratory motion is 4D CT or respira-
tion-correlated CT conventional and cone-beam
approaches.81–88,124,125 Four-dimensional data can be ana-
lyzed to determine the mean tumor position, tumor range of
motion for treatment planning,123,126–128 and the relation of
tumor trajectory to other organs and to a respiration
monitor.87 A limitation of 4D CT is that it is affected by
variations in respiratory patterns during acquisition.
Breathing-training techniques have been developed,56 how-
ever, even with these techniques artifacts can be observed.86
A 4D CT scan can be obtained in approximately a minute
of scanning time with a 16-slice CT scanner. Generally 8–25
complete CT data sets are reconstructed, the optimal use of
which has yet to be determined. Four-dimensional CT can be
used to reconstruct inhalation, exhalation, and slow CT
scans.
86 The MIP tool, as mentioned above, may be useful in
obtaining the tumor-motion-encompassing target volume.
Another motion-encompassing method is to derive a single
set out of the 4D CT scan where the tumor is close to its
time-averaged position. In that case, the expected dose blur-
ring effect of respiration can be accounted for in the CTV-
PTV margin.129
B. Respiratory gating methods
1. Introduction
Respiratory gating involves the administration of radia-
tion during both imaging and treatment delivery within a
particular portion of the patient’s breathing cycle, commonly
referred to as the “gate.” The position and width of the gate
within a respiratory cycle are determined by monitoring the
patient’s respiratory motion, using either an external respira-
tion signal or internal fiducial markers. As the beam is not
continuously delivered, gated procedures are longer than
nongated procedures.
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centers to account for respiratory motion during radiotherapy
of thoracic and abdominal tumors.53,56,76,130–134 Respiratory
motion can be characterized by two variables that are re-
corded as part of the respiration signal or the motion of the
internal anatomy. These variables are a displacement and
b phase. Accordingly, the method of gating is referred to as
either displacement gating or phase gating. The displacement
of the respiration signal measures its relative position be-
tween two extremes of breathing motion, namely, inhalation
and exhalation. In displacement-based gating, the radiation
beam is activated whenever the respiration signal is within a
pre-set window of relative positions. The second variable,
phase, is calculated by an algorithm from the respiration sig-
nal that must satisfy periodicity criteria; the radiation beam is
activated when the phase of the respiration signal is within a
pre-set phase window. Further details of displacement-based
and phased-based gating can be found in Vedam et al.145
Typically, a gate extends over a region of the breathing cycle
where the motion of the tumor is estimated to be less, gen-
erally end exhalation, or where the lung volume is maximal
end inhalation. The ratio of the beam-on time within the
gate to the overall treatment time is referred to as the duty
cycle and is a measure of the efficiency of the method. Some
tumor motion still occurs within the gate and is referred to as
“residual motion.”135 The choice of gate width is a tradeoff
between the amount of residual motion and duty cycle.
2. Gating using an external respiration
signal
Currently, the commercially available respiratory gating
system using an external respiration signal most widely dis-
cussed in publications is the Real-time Position Management
RPM system Varian Medical Systems, Palo Alto, CA;
thus, the procedures described here are applicable to this
device, although they can be generalized to other implemen-
tations. BrainLab Westchester, IL has an FDA-cleared res-
piratory gating device, called “ExacTrac Gating/Novalis Gat-
ing.” This device uses external markers for gating the
radiation beam, however, it has x-ray imaging capabilities
for determining the internal anatomy position and for verify-
ing the reproducibility of the internal anatomy during treat-
ment. Siemens Medical Systems Concord, CA also has an
FDA-approved linear accelerator gating interface and an An-
zai belt used for CT, also approved for use in therapy.
Three-dimensional video camera surveillance has also been
studied for respiratory motion management.136
Owing to its noninvasive nature, gating using an external
respiration signal can be applied to almost all 90%  pa-
tients. Breathing training may be beneficial in many cases
and can improve the likelihood of the patient completing the
simulation session. With the Varian RPM system, an infrared
reflective plastic box serving as the external fiducial marker
is placed on the patient’s anterior abdominal surface, typi-
cally midway between the xyphoid process and the umbili-
cus, and chosen to maximize the AP respiratory induced mo-
tion. The marker box should be placed nearly horizontally, to
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markers. If used during treatment, a durable skin mark at the
box location should be made at the time of imaging to ensure
reproducible positioning during treatment.
Prior to a gated CT scan, determination of gating param-
eters displacement or phase, exhalation or inhalation, duty
cycle are based on observation of the external respiration
signal and, if possible, tumor motion. In prospective gated
CT, a respiration gating system sends a trigger to the CT
scanner to acquire a CT slice. CT scan parameters slice
thickness, scanner rotation time, index, etc. remain the same
as those used for standard CT scans. Gate width and CT scan
rotation time should be similar. Shorter gate width results in
anatomic positions outside the intended gate to be included
in the image, while longer gate width results in more ana-
tomic motion occurring during the gate than is captured in
the CT image. Either situation is a potential source of error.
Note that not all CT scanners can perform prospective gat-
ing. The time required to acquire a prospective gated CT
scan depends on the patient’s respiratory period, since there
is one slice triggered per cycle. Irregular breathing can fur-
ther prolong the CT acquisition and/or lead to acquisition of
slices at the wrong part of the breathing cycle.
At treatment, marker block position and patient breathing
instructions are the same as during simulation. Once a stable
respiration trace has been established and gating thresholds
are verified, gated radiation delivery is initiated. The position
of the patient’s internal anatomy is verified using in-room
imaging. During treatment the therapist should be alert to the
graphical cues on the gating system monitor and be prepared
to intervene if the patient’s breathing is very irregular or
different from simulation. In-room images that show the tu-
mor, if possible, or an internal anatomic surrogate often the
diaphragm are helpful in assessing the performance of the
gating system over the course of treatment.81,137
For internal and external tracking systems, a possible
source of error is that the surrogate for tumor motion e.g.,
tracking blocks, strain gauges, etc. tracked by the gating
system does not accurately correspond with the time-
dependent target position Fig. 4. This can cause the timing
of the beam-on pulse to shift relative to the actual respiratory
cycle of the target. Where available, a minimum of 30 s of
imaging data fluoroscopy or CT ciné mode should be digi-
tally recorded in conjunction with the measured respiration
trace. The motion of the GTV—or anatomic surrogate such
as the diaphragm, if the GTV is not discernible—should be
compared with the external respiratory signal; a time delay
larger than 0.5 s between the two, if consistently observed,
should be corrected or accounted for when setting the gate
interval. An EPID-based approach for position verification in
this manner has been proposed by Berbeco et al.138
Dynamic test phantoms that simulate respiration are
needed, in order to test in vivo dosimetry and target localiza-
tion. There are several important factors: 1 The phantom
should produce cyclical motion similar to human respiration;
2 the gating feedback mechanism must detect phantom mo-
tion in a manner similar to the clinical process; 3 the device
should allow attachment of dose measuring detectors, such
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able and have a reasonable cost. Several custom-built phan-
toms have been made to meet these criteria,86,116,119,139–143
and commercial systems are available. Ramsey et al. de-
scribe further equipment QA tests for the Varian RPM respi-
ratory gating system.139
3. Gating using internal fiducial markers
This section focuses on the real-time tumor-tracking ra-
diotherapy system, developed jointly by Hokkaido Univer-
sity and Mitsubishi and based on radiographic detection of
implanted fiducials to gate radiation delivery.50,70,75,144–150
The fiducials 2 mm diameter gold spheres are implanted in
or near the tumor using a percutaneous or bronchoscopic
implanting technique. Fiducial position is tracked in all three
dimensions several times a second using a pair of stereotactic
kilovoltage x-ray imaging systems in combination with au-
tomatic detection software. The linear accelerator delivers
radiation when each fiducial is within an acceptable range of
the desired simulation position for both stereotactic x-ray
cameras.
Patient selection begins with assessment of tumor motion
prior to fiducial implant, to ensure maximum benefit to the
patient with this invasive procedure. The patient must be able
to tolerate the implant procedure and remain motionless on
the treatment couch for an extended treatment up to
45 min. For patients with lung cancer, pulmonary function
criteria are set, based on the recommendation of the pulmo-
nologist performing the implant. Because this technique has
been primarily used for stereotactic radiotherapy, most of the
patients have had relatively small lesions 4 cm in diameter
or less.
Treatment simulation uses a series of CT scans: a normal,
free breathing scan; a breath-hold scan at inhalation, and a
breath-hold scan at exhalation. Treatment plans are designed
on both the inhalation and exhalation set of CT images, and
the radiation oncologist selects the best plan based on the
dose distribution, assessing if increased lung sparing is found
on the inhalation plan. Six to ten static fields are used to
deliver 48 Gy in four fractions. The implanted fiducials are
identified in the planning system, and DRRs are generated to
replicate the images to be acquired in the treatment room.
At the beginning of each treatment, the fiducial path is
monitored for several breathing cycles and the patient repo-
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breathing cycle, the fiducial marker passes near the predicted
location. Two gates, one from each imaging system, must be
in coincidence to enable the beam. Treatment times are typi-
cally longer than 30 min, and the duty cycle varies by patient
and by the choice of respiratory cycle part to be used for
treatment.
QA procedures include confirmation that the coordinate
systems of the fluoroscopy unit and linear accelerator are
properly aligned. The coordinate system alignment should be
checked regularly, since there is a potential for drift with
both systems. The magnitude of marker motion detected by
the system needs to be verified, and it must also be assured
that the automated tracking of the internal fiducial markers is
robust.
4. Gated IMRT
Kubo and Wang115 demonstrated the feasibility of gating
the linear accelerator during a dynamic MLC delivery. They
showed that the dosimetry for gated IMRT delivery that in-
cluded motion 1D mechanical device was essentially the
same as that for delivery without motion. Target deformation
was not considered.
Respiratory gating techniques increase the treatment time.
This is more pronounced for gated IMRT in which the prod-
uct of the IMRT efficiency, typically 20%–50%, and the gat-
ing duty cycle, 30%–50%,76,133 leads to a 4- to 15-fold in-
crease in delivery time. Increasing dose rate from 300 to
600 MU/min can reduce the clock time by approximately
40%.134 Gated treatment session times are increased relative
to standard treatments by 2–10 min depending on patient
compliance.134 Considerations with increased delivery time
are patient comfort, increased likelihood of patient move-
ment and decreased patient throughput. During substantially
longer treatments, it has been suggested that tumor control
may be reduced due to the increased intrafraction repair of
sublethally damaged tumor cells.151,152
C. Breath-hold methods
1. Introduction
Breath hold methods have been predominantly applied to
lung cancer radiotherapy. Breast cancer radiotherapy may
FIG. 4. Comparison of external marker
block motion with internal motion of
the clinical target volume CTV for a
patient with a no phase shift and b
a patient with significant phase shift.
The respiratory gating thresholds are
set using the external marker block
motion. The beam-on pulses are high-
lighted in red over the internal CTV
position. From Ref. 204.also potentially benefit: although intrafraction motion is
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phragm pulls the heart posteriorly and inferiorly away from
the breast, and thus may reduce both cardiac and lung
toxicity.154–159
2. Deep-inspiration breath hold
A reproducible state of maximum breath hold deep-
inspiration breath hold or DIBH is advantageous for treating
thoracic tumors, because it significantly reduces respiratory
tumor motion and changes internal anatomy in a way that
often protects critical normal tissues. This section describes a
spirometer-monitored technique that was developed and
clinically implemented primarily for conformal radiation
treatments of NSCLC at the Memorial Sloan-Kettering Can-
cer Center MSKCC.61,160,161 There are at least two com-
mercial spirometry products that are compatible with the
DIBH technique: The VMAX Spectra 20C VIASYS Health-
care Inc., Yorba Linda, CA and the SpiroDyn’RX Dyn’R,
Muret, France. Forty-five patients have been treated with
DIBH at MSKCC 44 with NSCLC between 1998 and
2004; of these, eight were treated with DIBH in combination
with IMRT.
The DIBH technique involves verbally coaching the pa-
tient to a reproducible deep inhalation breath hold during
simulation and treatment. The patient breathes through a
mouthpiece connected via flexible tubing to a spirometer.
The naris is held closed with a nose clip. A computer pro-
gram displays and records the volume of air breathed in and
out as a function of time. The therapist coaches the patient
through a modified version of the slow vital capacity maneu-
ver, consisting of a deep inhalation, deep exhalation, second
deep inhalation and breath hold. The maneuver yields highly
reproducible lung inflation at approximately 100% capacity,
which can be maintained for 10–20 s patient specific.
Applicability of DIBH is limited by patient compliance:
Approximately 60% of the lung cancer patients at MSKCC
cannot perform the maneuver reproducibly enough to permit
its use; thus it is used only for compliant patients in whom
the significant lung inflation allows treatment to a higher
total dose 10% or more with acceptable normal tissue dose-
volume histograms and calculated lung complication
probability161 than is possible with free breathing treatment.
Following a brief DIBH practice session, the patient re-
ceives three helical CT scans in the treatment position: 1
With FB; 2 with spirometer-monitored deep inhalation
DI; and 3 with spirometer-monitored inhalation. The FB
and inhalation scans are for QA purposes, described below.
The FB scan also serves as the alternative treatment plan CT
if the patient cannot be completely treated with DIBH. The
simulation process—including immobilization, isocenter se-
lection, practice, 3 CT scans and resting between scans—
takes approximately 2 hr. The treatment plan and DRRs use
the DI breath-hold CT scan.
During treatment, the therapists are instructed to turn on
the beam only when the target breath-hold level has been
achieved and to stop treatment if the level has fallen below a
pre-set tolerance. For static conformal treatments at
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500–600 MU/min, a single breath hold is usually sufficient
for each field. More recently, IMRT in combination with
DIBH has been introduced for patients able to hold their
breath long enough to complete a field, approximately 20 s
for a typical beam-on time of 200 MU delivered at
600 MU/min with the sliding window technique.159 Treat-
ment sessions usually take 5–10 min longer than a similar
beam arrangement for an FB patient.
Patient-specific QA includes a check of the FB scan that
the patient’s state of respiration does not alter the position of
the spine, thus allowing positioning of the patient for treat-
ment while breathing normally. The inhalation scan is used
to set breath-hold tolerance levels by determining the motion
extent of the GTV for a known change in breath-hold
volume.160 In all imaging and treatment sessions, the thera-
pist is instructed to wait 1 s following breath hold before
turning on the beam, to allow for transient diaphragm
relaxation.160
The spirometer is calibrated with a 3 syringe for flow
rates between approximately 0.5 and 3  / s. The linearity of
spirometer integrated airflow versus actual syringe volume
is checked over a range of 0–3 in either flow direction;
typical linearity is within 2%. The calibration is checked
whenever the spirometer is gas sterilized, approximately ev-
ery 2 to 3 mo. Occasionally, drift of the spirometer is ob-
served following sterilization, which is usually correctable
by reassembling the device.
3. Active-breathing control
Active-breathing control ABC is a method to facilitate
reproducible breath hold.157,162 The ABC method was devel-
oped at William Beaumont Hospital and is currently com-
mercialized by Elekta Inc. Norcross, GA as the Active
Breathing Coordinator. A device with similar capabilities,
called the Vmax Spectra 20C, is available from VIASYS
Healthcare Inc. Yorba Linda, CA. The ABC apparatus can
suspend breathing at any predetermined position and is often
used at moderate or deep inhalation. It consists of a digital
spirometer to measure the respiratory trace, which is in turn
connected to a balloon valve. In an ABC procedure, the pa-
tient breathes normally through the apparatus. The operator
specifies the lung volume and stage of breathing cycle stage
to “activate” the system, at which the balloon valve is closed.
The patient is instructed to reach the specified lung volume,
typically after taking two preparatory breaths. The valve is
inflated with an air compressor for a pre-defined duration of
time, thereby “holding” the patient’s breath. The breath-hold
duration is patient dependent, typically 15–30 s, and should
be well tolerated to allow for repeated after a brief rest
period breath holds.
The Beaumont experience157,158,163 shows that a moderate
deep inhalation breath-hold mDIBH level set at 75% of
deep inspiratory capacity achieves substantial and reproduc-
ible internal organ displacement while maintaining patient
comfort. The intended mDIBH position is calculated from
the exhalation baseline and set during an initial training ses-
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help a patient achieve a steady breathing pattern.
Prior to the start of simulation a series of baseline mea-
surements should be made. Depending on the system, a pul-
monary function test PFT may be needed at this time to
provide reference data on the individual patient’s lung capac-
ity. Practice breath holds should be performed, and the pa-
tient instructed of various means of indicating discomfort
and signaling cessation of breath hold to the operators. The
CT scan should be optimized according to the maximum
reproducible length of breath hold in an immobilized posi-
tion; the timing of contrast should coincide with the appro-
priate breath-hold scan of the region of interest. The breath-
hold state, as well as duration of comfortable breath hold,
should be documented for use during treatment.
Treatment plans include a margin dependent on the in-
tended treatment verification strategy. If the patient is to be
treated daily without image guidance, the margin should con-
sider setup variation along with the long-term reproducibility
of ABC. The magnitudes of these margins for the patient
population in each clinic should be established for routine
application of the ABC procedure.
Treatment at each beam angle should be delivered in a
single breath hold, when possible. If a single breath-hold is
too long, then one can “break up” the single breath-hold into
two or more smaller breath-holds. These smaller breath-
holds should be recorded particularly if they are coordinated
with the delivery of IMRT segments on earlier accelerators
which require the “breakup” segments as individual beams.
Each beam needs to be delivered before releasing the patient
from breath-hold.
An important concern of patient-related QA is reproduc-
ibility of breath hold. It is essential that all operating person-
nel understand system functions and that the patient receive
and understand appropriate instruction. The process for es-
tablishing a breath hold at a given state e.g., exhalation,
inhalation, deep inhalation should be documented and
tested. A standard set of patient instructions for communica-
tion with the ABC operator and for emergency actions to
reestablish breathing is recommended. It is important to es-
tablish a hygienic procedure for cleaning reusable items
e.g., rubber mouthpiece.
The key functions that should be maintained and checked
frequently for safe use of an ABC system are the calibration
of airflow and volume, the ability to stop and restart air flow,
and the safety release mechanisms. It is important to under-
stand how the ABC unit establishes a breathing trace. Cur-
rent systems use mechanical spirometers or temperature sen-
sors. The calibration for the temperature sensor is absolute,
whereas the spirometer-based system operates by establish-
ing a baseline at each exhalation. Both systems are typically
calibrated using a 3.0 syringe. Apart from the vendor’s rec-
ommended calibration, the volume calibration should be
checked at different flow rates similar to those seen in pa-
tients. The minimum flow rate below which the mechanical
spirometer will not respond accurately should be established.
The equipment needed to provide ABC may affect the
processes of simulation and treatment. The air tube exiting
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trol, and ancillary hardware may occupy significant space,
possibly restricting the geometry of the CT scanner or treat-
ment unit. Prior to implementing ABC for a given body site,
the processes of immobilization, simulation and delivery
should be evaluated to determine an efficient means of inte-
grating the ABC unit and support equipment.
4. Self-held breath hold without respiratory
monitoring
In this technique the patient voluntarily holds his/her
breath at some point in the breathing cycle, during which
dose delivery occurs. A control system for its implementation
has been developed74,164 for the Varian C Series accelerators,
which makes use of the “Customer Minor CMNR” Inter-
lock. The patient depresses a hand-held switch to clear the
CMNR interlock, allowing the therapist to activate the beam.
Releasing the switch asserts the CMNR interlock, turning the
beam off and disabling any further delivery until the switch
is depressed again. Although only the therapist can turn the
beam on, both the therapist and the patient can turn the beam
off. The potential dosimetric advantages of increasing the
lung volume61,157,158,161,163 makes deep inhalation the pre-
ferred point for breath hold. Therefore, the earlier discussion
of DIBH and ABC would be similar to the advantages with
this method. The self-held breath-hold system is not com-
mercially available.
This mode of treatment relies heavily on the patient’s
ability to understand and perform a reproducible breath hold,
maintain it for at least 10 s, and simultaneously operate the
hand-held switch. Another selection criterion is the stability
of internal anatomy during breath hold: Some patients have
been observed to have continuous diaphragm motion during
breath hold, even though they believe they are holding their
breath. Following evaluation under fluoroscopy on a conven-
tional simulator, patients receive a breath-hold CT scan, in
which the scan sequence is segmented into 10 s acquisitions.
Patients are given a switch attached to a buzzer, which they
depress to indicate to the CT therapist when they are holding
their breath.
Determination of PTV margins should take into account
breath-hold reproducibility, as well as patient setup reproduc-
ibility and internal motion. Setup reproducibility will depend
on a department’s patient-positioning procedures and immo-
bilization devices and has been shown to have one standard
deviation of about 5 mm for typical techniques.18 Barnes et
al.74 showed that on average the margin for internal motion
in the SI direction was reduced from 12.9 to 2.8 mm using
the held-breath self-gating technique. Until sufficient statis-
tical data are available, it is recommended that the margin be
tailored to the individual patient by measuring the reproduc-
ibility during the simulator session, remembering that inter-
fractional variations do occur and should be considered. The
choice of breath-hold position will affect the volume of lung
and hence the dose distributions that are potentially achiev-
able.
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straightforward and efficient. When the therapist is ready to
switch the beam on, he/she instructs the patient over the
intercom to perform the breath-hold maneuver and depress
the switch. If the patient needs to breathe prior to the field
being completed, he/she simply releases the button to turn
off the beam, then repeats the breath-hold maneuver and
presses the button, allowing the therapist to resume treat-
ment.
The “held-breath self-gating” technique74 has been stud-
ied in 28 patients up to 2004 with eight of them treated
with the technique. As of this writing, the technique has been
used almost exclusively with an IMRT step-and-shoot deliv-
ery technique, typically five fields with approximately 10
segments per field, for a prescribed dose of 2.4 Gy/fraction.
Each field requires about 150–200 MU, corresponding with
15–20 s at a dose rate of 600 MU/min, and usually deliv-
ered in 2 or 3 breath holds. The increased time may become
burdensome if the patient can maintain the breath hold for
only the minimum 10 s; however, the majority of patients are
capable of significantly longer intervals, making it easier to
tolerate the procedure.
Important patient-related QA issues are ensuring accurate
setup, breath-hold stability and reproducibility. The amount
of anatomic motion seen during a breath hold and reproduc-
ibility in position between breath holds should be within
5 mm. If the tumor cannot be visualized with fluoroscopy, an
anatomic surrogate is used. This information is used to de-
termine the patient suitability and margin requirements.
There is minimal QA required for the equipment itself. Every
time it is used, there is visual confirmation on the treatment
console that the CMNR interlock is operational.
5. Self-held breath hold with respiratory monitoring
This technique uses a commercially available device
Varian RPM system, to monitor patient respiration and con-
trol dose delivery, but requires patients to voluntarily hold
their breath during a specific part of the respiratory cycle.
One advantage of this technique is that the simulation and
treatments can be delivered more efficiently than with FB
respiratory gated techniques, because the radiation is deliv-
ered continuously during the breath hold. An additional ad-
vantage is that patient respiration is constantly monitored,
and a beam-hold condition automatically occurs if the
breath-hold level deviates from the intended one.
At the time of consultation, patients are tested for their
ability to hold their breath for periods of 10 s. Patients must
also be able and willing to follow verbal breathing instruc-
tions and actively participate in their treatments. Pro-
grammed audio instructions such as “breathe in, breathe out,
hold your breath” are used to synchronize the helical CT
scan with breath hold. The patient holds his/her breath at
exhalation for periods of 7–15 s depending on ability. At the
end of a scan segment, the CT scanner is programmed to
issue a “breathe” command followed by a 20 s break. Typi-
cally multiple breath holds are required to scan the thorax.
Medical Physics, Vol. 33, No. 10, October 2006The CT therapist monitors the respiration trace on the RPM
system during the breath hold to verify that the trace is
within the threshold window.
When choosing PTV margins, the treatment planner
should take into account the patient setup uncertainty, breath-
hold reproducibility, treatment goals, frequency of portal im-
aging, and the presence or absence of implanted fiducial
markers. A means of reducing the number of MUs required
to deliver treatment, and thereby the number of breath holds
needed, is to eliminate the use of wedges and replace them
with forward planning techniques that utilize the MLC.165
For QA purposes, the dome of the diaphragm is delineated
and displayed on both the AP and lateral DRR reference
images for later comparison with portal images.
Prior to treatment, portal image verification of patient po-
sition and gating interval is performed. Dose is delivered
only when the marker position is within the gated interval.
The patient should be instructed to take a break at any time
by simply inhaling, which will trigger a beam-hold condi-
tion. In this event, the therapist depresses the “Beam-off”
button, allows the patient to take a 20 s break, and then
instructs the patient to “exhale and hold your breath when
ready,” for resumption of treatment.
Berson et al.166 have reported on 108 patients treated with
either an FB respiratory gating technique or the breath-hold
technique described in this section. They found several ad-
vantages to the breath-hold technique, including the elimina-
tion of a possible time lag between the tumor and the exter-
nal fiducial, efficiency gains in CT simulation and treatment,
and improved diaphragm positional reproducibility. Time to
deliver a treatment with the FB respiratory gating technique
was approximately twice that with the breath-hold technique.
Similarly, for a single-slice CT, scan time was approximately
one-half with breath-hold, relative to FB gating. The breath-
hold technique has the additional advantage of not requiring
specialized hardware or software to synchronize the CT
scanner with the respiratory gating system.
6. Breath hold in combination with IMRT
As indicated in the above sections, breath-hold methods
are applicable to IMRT. The technological requirements are
similar to those for respiratory gating: an accurate signal is
needed to enable and disable dose delivery. For dynamic
MLC, this signal controls the interruption and resumption of
leaf motion, whereas for helical tomotherapy, the signal in
addition would enable and disable couch motion. Another
possible approach is to incorporate breath holds into the
IMRT delivery sequence, that is, to segment the leaf-motion
sequence into active dose delivery and inactive no dose
periods, corresponding with the breath-hold and rest periods,
respectively. The duration of these periods would be set by
the planner. For helical tomotherapy, the gantry would con-
tinue to move during the rest period between breath holds;
when the treatment delivery was about to resume, the patient
could be made aware with audio and/or visual cues. Another
option specific to helical tomotherapy is delivery of a low,
but relatively uniform dose, to the entire longitudinal extent
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patient a partial fraction. This partial fraction would be re-
peated until the prescribed dose was delivered. The tech-
nique avoids problems with inner-field abutment between
breath holds to which other techniques are susceptible.
D. Forced shallow breathing with abdominal
compression
Forced shallow breathing FSB was originally developed
for stereotactic irradiation of small lung and liver lesions by
Lax and Blomgren at Karolinska Hospital in
Stockholm.167–169 and has been used elsewhere.8,170–176 The
technique employs a stereotactic body frame with an at-
tached plate that is pressed against the abdomen. The applied
pressure to the abdomen reduces diaphragmatic excursions,
while still permitting limited normal respiration. The accu-
racy and reproducibility of both the body frame and the pres-
sure plate have been evaluated by several groups, with the
most comprehensive assessment reported by Negoro et al.170
FSB has predominantly been applied to early stage lung and
liver tumors without mediastinal involvement or nodal dis-
ease. Typically, FSB has been used for stereotactic treat-
ments, although the technology is also applicable to conven-
tional lung treatments.
At treatment simulation, the patient is immobilized and
positioned using the stereotactic body frame SBF, consist-
ing of a rigid frame with an attached “vacuum pillow” that is
custom fitted to each patient. Tumor motion in the cranial—
caudal direction is assessed using a fluoroscopic simulator. If
the motion exceeds 5 mm, a small pressure plate is applied
to the abdomen such that the two superior, angled sides of
the plate are positioned 2 to 3 cm below the triangular rib
cage. The position of the bar that is attached to the SBF and
supports the plate is read from a scale on the side of the
frame and is reproduced at each treatment setup. The posi-
tion of the plate is controlled by a screw mechanism and is
measured on a scale marked on the screw, in order to repro-
duce the amount of compression at each treatment. Measure-
ments of diaphragm motion under fluoroscopy on different
days can be made to verify reproducibility.
Negoro et al. reported on 18 patients treated in 4 fractions
to a total dose of either 40 or 48 Gy. Daily orthogonal-view
portal imaging was used for patient alignment. Setup toler-
ance was a 3 mm total deviation from the planned position
using the SBF, requiring repositioning in 25% of the daily
setups. Ten of eighteen patients required abdominal compres-
sion: the range of motion before compression was 8–20 mm
12.3 mm mean, reduced to 2–11 mm 7.0 mm mean with
compression.
Patient-related QA at simulation involves evaluation of
tumor excursion under fluoroscopy from orthogonal direc-
tions, and application of abdominal compression when tumor
excursion exceeds clinical goals. Usually, the maximum
pressure that the patient can comfortably tolerate for the
treatment session duration is used. Because of difficulty in
reproducibly positioning the abdominal compression device,
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mor position, either via CT or by means of implanted fidu-
cials visible in radiographs.
E. Real-time tumor-tracking methods
Another means of accommodating respiratory motion is
to reposition the radiation beam dynamically so as to follow
the tumor’s changing position, referred to as real-time tumor
tracking. Under ideal conditions, tracking can eliminate the
need for a tumor-motion margin in the dose distribution,
while maintaining a 100% duty cycle for dose delivery. To
succeed, this method should be able to do four things: 1
Identify the tumor position in real time; 2 anticipate the
tumor motion to allow for time delays in the response of the
beam-positioning system; 3 reposition the beam; and 4
adapt the dosimetry to allow for changing lung volume and
critical structure locations during the breathing cycle.
1. Determining the tumor position
Detecting the tumor position is the most important and
challenging task in real-time tracking. Currently, there are
four possible means of locating the tumor during treatment:
1 Imaging of the tumor itself via, e.g., fluoroscopy; 2
imaging of fiducial markers implanted in the tumor; 3 in-
ference of the tumor position from surrogate breathing mo-
tion signals; and 4 nonradiographic tracking of an active or
passive signaling device implanted in the tumor. All of these
methods are currently under development or used clinically.
Direct tumor imaging: In certain situations, it can be pos-
sible to detect a lung tumor directly in radiographic/
FIG. 5. A lung tumor observed with a flat-panel amorphous silicon detector
forming part of the CyberKnife image-guided radiosurgery system. The tu-
mor has four gold fiducial seeds implanted in it to enhance its position
measurement. From Ref. 177.fluoroscopic images acquired during treatment. Figure 5
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detector at an exposure level of approximately 0.50 mGy.177
Most lung tumors will not present a well-defined, high-
contrast object suitable for automatic segmentation and im-
age registration, nor will tumors in the pancreas and liver.
Therefore, it is usually necessary to use an artificial marker
as a surrogate for tumor position.
Tumor location using implanted fiducial markers: One or
more high-Z metal markers implanted in lung, pancreas, or
liver tumors can be readily observed in x-ray images Fig. 5.
If only one fiducial marker is used it is not possible to deter-
mine from the images whether the fiducial has moved with
respect to the tumor. Three or more fiducial markers allow
measurement of tumor translation and rotation, and marker
migration can be inferred by monitoring the distance be-
tween markers. Murphy et al.72 have used 2 mm diameter
spherical gold balls sewn into the pancreas during explor-
atory laparotomy. Chen,73 Murphy,178 and Shirato70 have
used 0.8 by 4 mm cylindrical gold seeds implanted into or
near lung tumors percutaneously or bronchoscopically. Gold
fiducial markers are detectable in fluoroscopic images of the
abdomen and pelvis at exposures as low as 0.18 mGy per
image,70 allowing continuous monitoring in the treatment
room. Additional radiation dose from imaging should be con-
sidered; the report of AAPM Task Group 75 provides a de-
tailed review and guidelines for implementation of these
techniques. To reduce radiographic imaging exposure, hybrid
tumor-tracking techniques combine episodic radiographic
imaging and continuous monitoring of external breathing
signals, based on the premise that external motion surrogates
can accurately predict the internal tumor position in the time
interval between image acquisitions.73,78,177–181
Tumor position prediction based on surrogate breathing
signals: In situations when continuous fluoroscopic imaging
of the tumor is not feasible, it is necessary to infer the tumor
position from external respiration signals. If the correlation is
simple and stationary, it can be sufficient to measure it before
treatment with a fluoroscope, and used to predict tumor mo-
tion during treatment. However, the physiology of breathing
motion suggests that stationary correlation is not necessarily
a safe assumption.78,89–91,182,183 Nonstationary correlation
should be monitored and updated continually during treat-
ment by acquiring images of the tumor position synchro-
nously with the respiratory signal.179 This can be accom-
plished with adaptive filter algorithms, which are designed to
predict nonstationary signals by periodically updating the
empirical relationship between the input e.g., breathing and
the output e.g., tumor position signals.178
Nonradiographic tumor tracking: Seiler et al.184 have de-
scribed a miniature, implantable powered radiofrequency rf
coil that can be tracked electromagnetically in three dimen-
sions from outside the patient. Balter et al.185 have reported
on the performance of a wireless rf seed-tracking system for
tumor localization. The electromagnetic approach could pro-
vide an alternative to the use of radiological imaging to track
the tumor position.
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positioning response
The response of a beam-positioning system to a tumor
signal cannot occur instantaneously. Seppenwoolde et al.50
report a delay of 90 ms between the recognition of a fiducial
marker in a fluoroscopic image and the onset of irradiation in
their gated beam-delivery system. This includes computa-
tional time to locate the marker in the image as well as de-
lays in triggering the beam onset. Mechanical systems to
realign the beam have longer delays. The CyberKnife Ac-
curay, Sunnyvale, CA system described below has a
200 ms delay between acquisition of tumor coordinates and
repositioning of the linear accelerator. This delay is in addi-
tion to image acquisition, read-out, and processing times.
Repositioning an MLC aperture will likewise involve a time
delay of 100–200 ms or more.
The presence of a time delay requires that the tumor po-
sition be predicted in advance, so that the beam can be syn-
chronized to arrive at the actual position of the tumor once
the adjustment has been made. The problem is further com-
plicated in that a typical human breathing cycle, while nomi-
nally periodic, has significant cycle-to-cycle fluctuations in
displacement, as well as longer-term fluctuations in both dis-
placement and frequency.78,182 However, these fluctuations
are not purely random,186 suggesting the possibility to pre-
dict a particular breath cycle from the observed characteris-
tics of its predecessors. This is the basis for time series pre-
diction by an adaptive filter. Murphy et al.178 have analyzed
breathing prediction using a variety of adaptive filters and
have found that the tumor position can be predicted with up
to 80% accuracy i.e., 20% residual uncertainty in the pres-
ence of a 200 ms system delay, but accuracy degrades rap-
idly with longer delay intervals, which is consistent with
findings by Sharp et al.180 and Vedam et al.187
3. Repositioning the beam
There are presently two real-time beam-positioning meth-
ods. The first one is MLC repositioning.116,188–195 The second
method uses a robotic manipulator to move the entire linear
accelerator with six degrees of freedom. In this approach, the
robot CyberKnife image-guided radiosurgery system is
coupled through a real-time control loop to an imaging sys-
tem that monitors the tumor position and directs the reposi-
tioning of the linear accelerator.72,73,78,179 It has the advan-
tage of adapting to the full 3D motion of the tumor. Both
methods can use the same algorithms to satisfy the require-
ments for tumor position identification, time delay compen-
sation, and dosimetric corrections for breathing. It should be
noted that cardiac motion can also cause tumor motion on
the order of 2 mm.50,72 In principle, couch,196 block,197 or
jaw motion can also be used for beam repositioning.
4. Correcting the dosimetry for breathing effects
The effect of breathing on dosimetry was recently dis-
cussed by Bortfeld et al.198 The treatment-planning imaging
study used to calculate the dosimetry necessarily captures the
anatomy in one static configuration, whereas during breath-
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ally changing. This perturbs the attenuation of the treatment
beam and changes the relative positions of tumor, normal
tissue, and critical structures. Compared with the alternative
of treating with a motion margin, or missing the target com-
pletely, these issues are second-order effects, but their impact
needs to be studied.
5. Recommendations for the implementation of a
real-time tracking response to respiratory
motion
Observations of lung tumor motion show that it can fol-
low a complex 3D trajectory.50 Therefore, a tracking method
should preferably provide 3D coordinates of the tumor, al-
though 2D motion in the plane perpendicular to the beam
direction is also acceptable. Three-dimensional information
requires simultaneous acquisition from dual fluoroscopes.
Breathing irregularity makes it difficult to predict more than
0.5 s with sufficient accuracy to give real-time tracking a
clear advantage over other respiratory compensation meth-
ods. Therefore, the total time delay of a real-time tracking
system should be kept as short as possible and, in any case,
not more than 0.5 s.
6. Quality assurance
These procedures must address two fundamental sources
of potential error in dose delivery: 1 Determination of the
tumor position as a function of time and 2 calibration of the
spatial relationship between the tracking coordinate system
and the beam-delivery coordinate system.
Sources of tumor-position uncertainties during tracking
are essentially the same as for gating, and QA for both meth-
ods will follow a similar methodology. The accurate transla-
tion of tumor coordinates from the tracking device to the
beam-alignment system is of extreme importance. If the tu-
mor is tracked directly via radiographic or fluoroscopic im-
aging, the imaging system should either have a mechanically
rigid relationship with the beam delivery system or be local-
izable with an in-room tracking system, which itself will
introduce imprecision to the tumor/beam alignment. In hy-
brid tracking that involves imaging coordinated with external
respiratory signals, the imaging and the external monitoring
systems should maintain a calibrated relationship with each
other and with the beam-delivery system. The CyberKnife
system uses a specially designed composite imaging/
dosimetry phantom to check the geometrical relationship be-
tween tracking system and beam-delivery systems. The
phantom is localized with the imaging/tracking system and
irradiated with the planned dose. The position of the deliv-
ered dose, relative to the plan, reveals any systematic co-
alignment errors. This test takes approximately 1.5 h and
should be performed monthly.
7. Synchronization of IMRT with motion
The most sophisticated and yet challenging methods in-
volve those that attempt to synchronize IMRT delivery with
116respiratory motion. Keall et al. demonstrated the feasibil-
Medical Physics, Vol. 33, No. 10, October 2006ity of such an approach. In this study, the respiratory motion
as simulated by a 1D mechanical device was superimposed
on the original planned intensity pattern. They showed that
the dosimetric results obtained with the motion-synchronized
approach were very similar within a few percent to those
for the static IMRT delivery that did not include motion.
Target deformation was not considered.
One of the key dependencies of respiratory synchronized
approaches is the derivation of a stable input trace that accu-
rately reflects the target’s motion during respiration. In a
study of this topic, Neicu et al.188 termed this reference
breathing trace the “average tumor trajectory ATT.” Using
11 lung data sets obtained from a real-time tracking system,
they found that an ATT could be derived from patient data
and applied successfully. However, coaching was recom-
mended as a means to make the ATT more reliable. Delivery
efficiency is driven by the accuracy of the ATT, since the
system turns off radiation whenever the input trace deviates
from the ATT and waits until agreement is reestablished.
Other dynamic MLC-based approaches to respiration-
synchronized radiotherapy have also been proposed.189–195
Zhang et al. describe an approach in which an ATT is derived
and used during planning in conjunction with a 4D CT data
set and applied this method to helical tomotherapy
planning.199 The transition of one breathing stage to the next
is anticipated in the planning stages using the CT data as
opposed to being superimposed after planning.
VII. SUMMARY AND RECOMMENDATIONS
This section summarizes the Task Group report and gives
recommendations for both the clinical and, particularly, the
technical management of patients for whom respiratory mo-
tion may be a concern and areas requiring further study. It is
important to restate here that respiratory motion is just one of
the many geometric errors in thoracic and abdominal radio-
therapy and that respiratory patterns change from cycle to
cycle and day to day.
Unless imaging the entire treatment volume continuously,
respiratory surrogates are used to infer tumor motion. Inter-
nal markers implanted in the tumor offer the most accurate
information regarding target position during treatment; how-
ever, the benefits of accuracy need to be weighed against the
cost and invasive procedure of implanting markers in tumors
as well as against possible marker migration. If external
markers are used as the respiratory surrogate, the relationship
with the internal target should be established, for example,
by sampling the target position fluoroscopically for brief pe-
riods of time at a number of intervals.
A. Clinical process recommendations
The Task Group recommends that for patients in whom
respiratory motion may be a concern that the flowchart in
Fig. 6 be followed. Box 1 of Fig. 6 asks if a method of
measuring motion is available. EORTC guidelines95 recom-
mend that “An assessment of 3D tumor mobility is essential
for treatment planning and delivery in lung cancer.” When
measuring tumor motion, the motion should be observed
3893 Keall et al.: Respiratory motion in radiation oncology 3893over several breathing cycles if possible. It is important to
note that respiratory patterns change over time. If no method
exists for measuring motion, for example, with a standard
respiratory gated CT procedure, the prudent approach is to
assume that motion is significant and treat with respiratory
management box 6. If a method of measuring motion, such
as fluoroscopy, is readily available box 1, it can be worth-
while to measure the motion for three reasons:
1 If the magnitude of the motion is significantly small
5 mm of range of motion in any direction, relative to
other errors in radiotherapy, the extra effort of using
respiratory management techniques is unwarranted box
2, unless significant normal tissue sparing as deter-
mined by your clinic can be gained with the respiration-
management technique. The 5 mm motion-limit crite-
rion value was chosen, because this level of motion can
cause significant artifacts and systematic errors during
imaging procedures. Note that due to respiratory varia-
tions the motion magnitude may increase or decrease
during the treatment course, and that if practical the mo-
tion can be re-evaluated during treatment.
2 If a patient-specific tumor-motion measurement is made,
FIG. 6. Recommended clinical process for patients with whom respiratory
motion during the radiotherapy process is a concern.this information can and should be used in the CTV-to-
Medical Physics, Vol. 33, No. 10, October 2006PTV margin used for treatment planning. If a respiratory
management device is not used, the dosimetric effect of
the motion should be considered and an appropriate
margin should be derived. The most simple way is to
consider the entire range of motion when establishing
the internal margin.42 If respiratory management devices
are used, only the motion expected during the radiation
treatment delivery should be considered when establish-
ing the respiratory motion component of the internal
margin.
3 If the motion measurement and respiratory signal to be
used for treatment are acquired simultaneously, phase
shifts or time lags between the internal and external mo-
tion can be calculated and corrected.
The Task Group recommends that respiratory management
techniques be considered if either of the following conditions
occur:
• A greater than 5 mm range of motion is observed in any
direction; or
• significant normal tissue sparing as determined by your
clinic can be gained through the use of a respiration
management technique box 2 of Fig. 6.
The recommended 5 mm motion-limit criterion value may
be reduced for special procedures, such as stereotactic body
radiotherapy. This value may be reduced in the future as
other errors in radiotherapy, such as target delineation and
setup error, are reduced, with respiratory motion thereby be-
coming the accuracy limiting factor. Furthermore, depending
on practicality, the motion may be re-evaluated during the
treatment course.
If a method of respiratory management is not available
box 3 of Fig. 6, as is the case with most facilities, the
guidelines in Section VI A should be followed. If a method
of respiratory management is available, the next question to
be answered box 4 of Fig. 6 is whether the clinical goals
can be achieved without explicit respiratory management.
This question is very complex and difficult to assess a priori.
An example could include palliative cases in which the
treatment-related toxicity is expected to be low. Another ex-
ample is the irradiation of very small metastases where even
with a substantial margin the irradiated volumes may still be
small enough that no significant risk of treatment-related tox-
icity exists. A confounding factor is that the patient’s future
need for radiation therapy is unknown, and patients with me-
tastases are often treated multiple times, which may cause
the extra dose to become a concern.
The next important question to be answered is whether an
individual patient can tolerate the respiratory management
technique box 5. As outlined previously in the report, there
are many factors that may cause patients to be unsuitable for
a particular respiratory management technique, and, in most
cases, there are few predictive factors to determine who will
or will not be able to tolerate the procedure. The prudent
approach is to try respiratory management and, if unsuccess-
ful, to treat without explicit respiratory management.
3894 Keall et al.: Respiratory motion in radiation oncology 3894At the time of printing, some systems do not have soft-
ware interlocks in the record-and-verify systems that prevent
treatment of the wrong patient with respiration management
devices or vice versa or the use of the wrong patient pa-
rameters. Thus, the Task Group recommends that manufac-
turers of the respiratory management devices collaborate
with record-and-verify system companies to ensure that the
relevant parameters for a patient’s treatment are included in
the patient’s electronic file.
B. Treatment-planning recommendations
When deriving CTV–PTV margins for treatment plan-
ning, the following factors specific to respiratory motion
should be taken into account:
• The distortion of the planning CT due to respiratory
motion-induced artifacts is an important source of sys-
tematic error these artifacts are found to varying de-
grees in free-breathing, slow, gated, and 4D CT scans.
• If a structure, such as the chest wall or diaphragm, is
used as a surrogate for tumor motion for the purpose of
breath hold, beam gating or tracking, without observing
the tumor directly during treatment, there will be uncer-
tainties in the displacement and phase relationship be-
tween the surrogate and the tumor.78,89–91
• There are variations within and between respiratory
cycles and also residual motion during both respiratory
gating and breath-hold procedures.
• If a patient-specific tumor-motion measurement is
made, the information should be used in the CTV-to-
PTV margin used for treatment planning. If a respira-
tory management device is not used, the entire range of
motion should be considered when establishing the in-
ternal margin.42
Other factors such as setup error and tumor changes during
the course of radiotherapy are common to all sites.42 An
obvious problem is that the errors listed above have yet to be
adequately quantified, and, thus, informed guesses as to the
magnitude of these errors need to be made. In areas where
knowledge is lacking, the next section details a list of rec-
ommendations for further investigations to fill in the knowl-
edge gaps.
Due to the complex nature of radiation transport in low-
density regions such as the lung, the Task Group recom-
mends that the most accurate dose calculation available be
used.
C. Personnel recommendations
The Task Group recommends that, due to the complexity
of the management of the respiratory motion problem and
the technology used, a qualified medical physicist be present
at all treatment-simulation virtual or otherwise imaging
sessions in which respiratory management devices are used
and also for at least the first treatment for each patient. A
physicist should also be available for consultation during the
treatment-planning process and for all treatment sessions.
Medical Physics, Vol. 33, No. 10, October 2006The physicists involved with the procedures should have an
appropriate understanding of the equipment and have at-
tended, when possible, training on the specific devices
used. In certain cases, a well-trained radiation oncology pro-
fessional may perform the tasks of a qualified medical physi-
cist, provided that a qualified medical physicist is available
for consultation. Additional dosimetry or therapy staff may
also be needed during imaging and treatment to operate or
assist on the operation of the respiratory management de-
vices.
D. Quality assurance recommendations
Strict QA procedures for the imaging, planning, and de-
livery of radiotherapy using respiratory management devices
are required to ensure the safe and effective use of these
devices. QA procedures are given in Sec. V B and discussed
under each described motion management technique. The
Task Group recommends that these procedures be docu-
mented and followed and that the results of the procedures
be appropriately documented and stored. Where possible,
QA of each fraction delivered using respiratory management
devices should be pursued as well.
E. Recommendations for further investigations
The management of respiratory motion in radiation oncol-
ogy is an evolving field with many current and, no doubt,
future issues still to be adequately addressed. The Task
Group recommends research in the following areas for which
the current scientific knowledge is absent or sparse:
• Changes in respiratory patterns between treatment
simulation and treatment;
• relationship between respiration signals and tumor mo-
tion and changes in this relationship throughout a
course of radiotherapy;
• tumor deformation from cycle to cycle and day to day;
• new imaging methods at treatment to directly detect tu-
mor positions or to verify the relationship between res-
piration signals and tumor motion;
• methods, such as audiovisual feedback, that can im-
prove respiration reproducibility throughout the course
of radiotherapy;
• effects of cardiac and gastrointestinal motion on tho-
racic radiotherapy.
• relationships between normal tissue and tumor motion,
particularly for normal tissue that is dose limiting
and/or from which a useful motion signal for imaging
and treatment can be obtained;
• more accurate determination of the magnitude of respi-
ratory motion that should be explicitly managed using
the respiratory management techniques—given other
errors in radiotherapy;
• optimal respiratory motion management strategies
stratified by disease site, patient characteristics, and
treatment regimen;
3895 Keall et al.: Respiratory motion in radiation oncology 3895• respiratory motion patterns and treatment implications
in children and young adults treated with radiotherapy
for lymphoma and other pediatric diseases involving
thoracic radiotherapy;
• robust deformable image-registration algorithms to fa-
cilitate dose accumulation due to anatomy deformation;
• treatment-planning solutions that can be integrated into
commercial treatment-planning systems;
• appropriate margin formalisms including respiratory
motion for the various respiratory motion management
strategies;
• deformable phantoms to which anatomically accurate
respiratory motion can be applied;
• analysis of clinical outcome data in the presence of res-
piratory motion and other errors.
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